Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Dara-RVD in newly diagnosed multiple myeloma: Real-world clinical practice

View Full Paper
Ask AI
Bookmark
Share

Authors

SKStanislav S. KamyshanovNZNikita ZemlyakovBKBella Khakulova

Discussion

Loading...

Member takes

Overview

Real-world evidence shows high efficacy of Dara-RVd treatment in high-risk multiple myeloma patients, implying shifts in standard care practices.

Key Points

  • Overall response rate reached 83% among high-risk multiple myeloma patients receiving Dara-RVd induction therapy, highlighting effective management.
  • Among 12 patients treated, 7 achieved MRD-negative status after induction, with sustained responses following autologous stem cell transplantation.
  • Assessment utilized International Myeloma Working Group criteria, alongside analysis of circulating tumor cells for risk stratification and monitoring.
  • Results indicate potential for the Dara-RVd regimen to alter treatment paradigms, necessitating careful monitoring of immunodeficiency and other complications.

Cite This Study

Kamyshanov et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1d7https://doi.org/10.1182/blood-2025-7591
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results2025
  2. 2Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population2025
  3. 3Real-world stratified treatment strategies in transplant-eligible newly diagnosed multiple myeloma: A multicohort study2025
  4. 4Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China2025
  5. 5Real-world experience with first-line regimens in transplant-ineligible patients with multiple myeloma2025